Paclitaxel
Top View
- Cancer Drug Costs for a Month of Treatment at Initial Food
- Pros and Cons Controversy on Molecular Imaging and Dynamic
- Effect of the St. John's Wort Constituent Hyperforin on Docetaxel Metabolism by Human Hepatocyte Cultures
- Safety Data Sheet
- Disease Site-Delivering Pharmaceutical Compositions Comprising Paclitaxel
- Appendix B - Product Name Sorted by Applicant
- A Phase I Study of Paclitaxel for Mobilization of Peripheral Blood Progenitor Cells
- Leiodermatolide, a Novel Marine Natural Product, Has Potent Cytotoxic
- Cyclophosphamide and Paclitaxel As Initial Or Salvage Regimen for the Mobilization of Peripheral Blood Progenitor Cells
- Steroidal and Non-Steroidal Third-Generation Aromatase Inhibitors Induce Pain-Like Symptoms Via TRPA1
- Hypericum Perforatum)
- Breast Pathway Group – EC X 4 – Paclitaxel X 4 (3-Weekly): Epirubicin & Cyclophosphamide X 4 Followed by Paclitaxel X 4 (3-Weekly) in Early Breast Cancer
- Hypericum Perforatum Monograph
- AB 2588 EICG Appendix a Combined List of Substances
- Effects of Hypericum Perforatum Extract on Oxaliplatin-Induced Neurotoxicity: in Vitro Evaluations
- Paclitaxel (Taxol®) (“Pac-Li-TAKS-El”)
- Sequence-Dependent Hematological Toxicity Associated with the 3-Hour Paclitaxel/Cyclophosphamide Doublet’
- Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer